Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients
复制标题
DOI：
10.1002/pds.1507
复制
发表时间：
2008-01-01
影响因子：
2.6
通讯作者：
Habel, Laurel A.
中科院分区：
文献类型：
--
作者：
Friedman, Gary D.;Flick, E. Dawn;Habel, Laurel A.
目的确定他汀类药物使用者的癌症风险。方法对加利福尼亚州北部一项综合医疗保健计划的订阅者在首次接受他汀类药物记录后长达9.4年的癌症风险进行评估。结果361859名使用他汀类药物的患者中，大多数服用洛伐他汀或辛伐他汀，或同时服用洛伐他汀和辛伐他汀。分析结果滞后2年，使用时间超过5年。大多数观察到的关联可能是由于偶然或混淆造成的。少数几个似乎不太容易解释的关联是甲状腺、食道癌和尿道癌的风险增加，以及男性结肠癌风险的降低。肺癌风险增加是女性中唯一名义上具有统计学意义的正相关关系，可能部分归因于她们的吸烟习惯。结论总体而言，这项研究没有提供他汀类药物导致或预防癌症的有力证据。版权所有(C)2007 John Wiley&Sons，Ltd.
Purpose Determine the risk of cancer in statin users.Methods Risk of cancer in up to 9.4 years after first recorded receipt of statins was evaluated in subscribers of an integrated health care program in northern California. Statin use and cancer development were ascertained from the program's pharmacy records and cancer registry from August 1994 to December 2003.Results Most of the 361859 statin users received lovastatin, simvastatin or both. Results are presented from analyses with 2-year lag and use for over 5 years. Most of the observed associations were likely due to chance or confounding. The few associations that seemed less readily explainable were increased risk of cancers of the thyroid, esophagus and urinary tract and decreased risk of colon cancer in men. Increased risk of lung cancer was the only nominally statistically significant positive association in women and could be partially attributable to their smoking habits.Conclusions Overall this study provided no strong evidence of either causation or prevention of cancer by statins. Copyright (c) 2007 John Wiley & Sons, Ltd.